Marcela V. Maus

32.4k total citations · 19 hit papers
207 papers, 14.0k citations indexed

About

Marcela V. Maus is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Marcela V. Maus has authored 207 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Oncology, 58 papers in Immunology and 54 papers in Molecular Biology. Recurrent topics in Marcela V. Maus's work include CAR-T cell therapy research (183 papers), Nanowire Synthesis and Applications (46 papers) and Virus-based gene therapy research (45 papers). Marcela V. Maus is often cited by papers focused on CAR-T cell therapy research (183 papers), Nanowire Synthesis and Applications (46 papers) and Virus-based gene therapy research (45 papers). Marcela V. Maus collaborates with scholars based in United States, United Kingdom and Germany. Marcela V. Maus's co-authors include Carl H. June, Rebecca C. Larson, Bruce L. Levine, Yangbing Zhao, Irene Scarfò, Matthew J. Frigault, Andrea Schmidts, Stephan A. Grupp, Michael Kalos and Stefanie R. Bailey and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Marcela V. Maus

189 papers receiving 13.8k citations

Hit Papers

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engine... 2007 2026 2013 2019 2013 2007 2021 2018 2014 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
    2013 693 citations Gregory L. Beatty, Andrew R. Haas et al. Cancer Immunology Research profile →
  2. CD8+ T-cell responses to adeno-associated virus capsid in humans
    2007 573 citations Marcela V. Maus et al. profile →
  3. Recent advances and discoveries in the mechanisms and functions of CAR T cells
    2021 553 citations Rebecca C. Larson, Marcela V. Maus profile →
  4. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
    2018 542 citations Li Tang, Yiran Zheng et al. Nature Biotechnology profile →
  5. Antibody-modified T cells: CARs take the front seat for hematologic malignancies
    2014 490 citations Marcela V. Maus, Carl H. June et al. Blood profile →
  6. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
    2018 478 citations Simon F. Lacey, Marcela V. Maus et al. profile →
  7. T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
    2013 476 citations Marcela V. Maus, Andrew R. Haas et al. Cancer Immunology Research profile →
  8. Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
    2019 453 citations Benjamin P. Kleinstiver, Irene Scarfò et al. Nature Biotechnology profile →
  9. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
    2015 434 citations Marcela V. Maus, Simon F. Lacey et al. profile →
  10. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
    2019 426 citations Bryan D. Choi, Ana P. Castaño et al. Nature Biotechnology profile →
  11. Engineering and Design of Chimeric Antigen Receptors
    2018 325 citations Marcela V. Maus et al. profile →
  12. The Emerging Landscape of Immune Cell Therapies
    2020 294 citations Marcela V. Maus et al. profile →
  13. Ibrutinib treatment improves T cell number and function in CLL patients
    2017 288 citations Joseph A. Fraietta, Carl H. June et al. profile →
  14. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
    2022 225 citations Rebecca C. Larson, Michael C. Kann et al. profile →
  15. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
    2024 210 citations Bryan D. Choi, Matthew J. Frigault et al. profile →
  16. CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells
    2021 150 citations Andrea Schmidts, Marcela V. Maus et al. Nature Biotechnology profile →
  17. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
    2024 132 citations Bruce L. Levine, Marcela V. Maus et al. profile →
  18. The future of engineered immune cell therapies
    2022 124 citations Darrell J. Irvine, Marcela V. Maus et al. Science profile →
  19. CAR T Cells and T-Cell Therapies for Cancer
    2024 86 citations Marcela V. Maus et al. profile →

Peers

Marcela V. Maus
Michael C. Milone United States
Isabelle Rivière United States
Michael Kalos United States
J. Joseph Melenhorst United States
Simon F. Lacey United States
Barbara Savoldo United States
Renier J. Brentjens United States
Crystal L. Mackall United States
Steven A. Feldman United States
Stephen Gottschalk United States
Michael C. Milone United States
Marcela V. Maus
Citations per year, relative to Marcela V. Maus Marcela V. Maus (= 1×) peers Michael C. Milone

Countries citing papers authored by Marcela V. Maus

Since Specialization
Citations

This map shows the geographic impact of Marcela V. Maus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcela V. Maus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcela V. Maus more than expected).

Fields of papers citing papers by Marcela V. Maus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcela V. Maus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcela V. Maus. The network helps show where Marcela V. Maus may publish in the future.

Co-authorship network of co-authors of Marcela V. Maus

This figure shows the co-authorship network connecting the top 25 collaborators of Marcela V. Maus. A scholar is included among the top collaborators of Marcela V. Maus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcela V. Maus. Marcela V. Maus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gustine, Joshua, Andrew R. Branagan, Diana Cirstea, et al.. (2025). Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma. Blood Advances. 9(12). 3026–3030. 1 indexed citations
2.
Bouffard, Amanda A., Mark B. Leick, Nicholas J. Haradhvala, et al.. (2025). On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models. Nature Communications. 16(1). 9650–9650.
3.
Ellithi, Moataz, Magdi Elsallab, Matthew A. Lunning, et al.. (2024). Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data. Transplantation and Cellular Therapy. 31(2). 71.e1–71.e14. 11 indexed citations
4.
Elsallab, Magdi, Florence T. Bourgeois, & Marcela V. Maus. (2024). National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells. Transplantation and Cellular Therapy. 30(6). 626.e1–626.e11. 4 indexed citations
5.
6.
Punekar, Salman R., J. Randolph Hecht, Diane M. Simeone, et al.. (2024). EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).. Journal of Clinical Oncology. 42(16_suppl). TPS2699–TPS2699. 5 indexed citations
7.
Nix, Matthew A., Huimin Geng, Rebecca C. Larson, et al.. (2023). Affinity Matured CD72 CAR-T Improves Efficacy Versus Low Antigen Density B-Cell Non-Hodgkin Lymphoma Models. Blood. 142(Supplement 1). 2068–2068. 1 indexed citations
8.
Larson, Rebecca C., Michael C. Kann, Charlotte Graham, et al.. (2023). Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nature Communications. 14(1). 7509–7509. 23 indexed citations
9.
Pourzia, Alexandra L., Michael Olson, Stefanie R. Bailey, et al.. (2023). Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells. Cell Death and Disease. 14(4). 267–267. 9 indexed citations
10.
Irvine, Darrell J., Marcela V. Maus, David Mooney, & Wilson W. Wong. (2022). The future of engineered immune cell therapies. Science. 378(6622). 853–858. 124 indexed citations breakdown →
11.
Jan, Max, Irene Scarfò, Rebecca C. Larson, et al.. (2021). Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Science Translational Medicine. 13(575). 180 indexed citations
12.
Schmidts, Andrea, Amanda A. Bouffard, Angela C. Boroughs, et al.. (2020). Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. Journal for ImmunoTherapy of Cancer. 8(2). e000990–e000990. 18 indexed citations
13.
Frigault, Matthew J., Jörg Dietrich, María Martínez-Lage, et al.. (2019). Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 134(11). 860–866. 160 indexed citations
14.
Fishman, Jay A., et al.. (2018). Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. Clinical Infectious Diseases. 69(6). 909–920. 54 indexed citations
15.
Scarfò, Irene, Maria Ormhøj, Matthew J. Frigault, et al.. (2018). Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 132(14). 1495–1506. 105 indexed citations
16.
Tang, Li, Yiran Zheng, Mariane B. Melo, et al.. (2018). Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nature Biotechnology. 36(8). 707–716. 542 indexed citations breakdown →
17.
Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research. 22(11). 2684–2696. 141 indexed citations
18.
Fesnak, Andrew D., et al.. (2016). CAR-T Cell Therapies From the Transfusion Medicine Perspective. Transfusion Medicine Reviews. 30(3). 139–145. 59 indexed citations
19.
Beatty, Gregory L., Andrew R. Haas, Marcela V. Maus, et al.. (2013). Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies. Cancer Immunology Research. 2(2). 112–120. 693 indexed citations breakdown →
20.
Maus, Marcela V., et al.. (1999). Prolactin as a Chemoattractant for Human Breast Carcinoma. Endocrinology. 140(11). 5447–5450. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael C. Milone Breakdown of academic impact, for papers by Isabelle Rivière Breakdown of academic impact, for papers by Michael Kalos Breakdown of academic impact, for papers by J. Joseph Melenhorst Breakdown of academic impact, for papers by Simon F. Lacey Breakdown of academic impact, for papers by Barbara Savoldo Breakdown of academic impact, for papers by Renier J. Brentjens Breakdown of academic impact, for papers by Crystal L. Mackall Breakdown of academic impact, for papers by Steven A. Feldman Breakdown of academic impact, for papers by Stephen Gottschalk
Rankless by CCL
2026